The paste serves as a place holder in the defect and provides ideal conditions for the ingrowth of blood vessels. At the same time, the hydrogel structure of the hyaluronic acid supports the metabolism for new bone generation. In this way new bone grows at the interface with the surrounding healthy bone as the CERASORB® Ortho Paste is resorbed.

The new product, for which a patent has been filed, is expected to be used mainly for filling smaller defects, for example in hand and foot surgery, for smaller bone cysts, for filling of spinal cages, and for minimally invasive sinus lift procedures.

„From the side of the orthopedic and trauma surgeons, there is a strong interest in simple and easy to use materials, particularly for difficult to reach defects", commented Hans-Dieter Rössler, CEO of curasan AG. „We can now fulfill this wish with our latest development."

Background information about curasan AG:

Publicly traded curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine and specialised on bone and tissue regeneration. The company has developed a future-oriented product pipeline in synthetic bone substitutes and bone regeneration material. Some of these various new developments already have been brought to market, and additional products will follow. These biomaterials will be distributed in different submarkets by well-positioned contractual partners as well as by curasan's own sales organisation. www.curasan.com

Press contact:

curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.curasan.de

fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)6172 27159-20
Fax +49 (0)6172 27159-69
This email address is being protected from spambots. You need JavaScript enabled to view it.